• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

氯喹和羟氯喹治疗干眼症

Chloroquine and Hydroxychloroquine in the Treatment of Dry Eye Disease.

作者信息

Prinz Julia, Maffulli Nicola, Fuest Matthias, Walter Peter, Hildebrand Frank, Migliorini Filippo

机构信息

RWTH University Hospital of Aachen, Pauwelsstraße 30, 52074 Aachen, Germany.

Department of Medicine, Surgery and Dentistry, University of Salerno, 84081 Fisciano, Italy.

出版信息

Diseases. 2023 Jun 12;11(2):85. doi: 10.3390/diseases11020085.

DOI:10.3390/diseases11020085
PMID:37366873
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10297605/
Abstract

The role of chloroquine (CQ) and hydroxychloroquine (HCQ) in the management of dry eye disease is still unclear. This systematic review and meta-analysis investigates the efficacy and feasibility of CQ and HCQ in patients with dry eye disease. In February 2023, PubMed, Embase, Google Scholar, and Web of Science were accessed. Data from 462 patients (mean age 54.4 ± 2.8 years) were collected. Compared to baseline, the tear breakup time ( < 0.0001) and Schirmer I test ( < 0.0001) were significantly increased, and the Ocular Surface Disease Index (OSDI, < 0.0001) and corneal staining ( < 0.0001) were significantly decreased at the last follow-up in the CQ/HCQ group. At the last follow-up, the OSDI was significantly lower in the CQ/HCQ group compared to the control group ( < 0.0001). Corneal staining was significantly greater in the control group compared to the CQ/HCQ group ( < 0.0001). The Schirmer I test showed no significant difference between the groups ( = 0.2). Altogether, CQ and HCQ improved the symptoms and signs of dry eye disease.

摘要

氯喹(CQ)和羟氯喹(HCQ)在干眼病治疗中的作用仍不明确。本系统评价和荟萃分析旨在研究CQ和HCQ对干眼病患者的疗效和可行性。2023年2月,检索了PubMed、Embase、谷歌学术和科学网。收集了462例患者(平均年龄54.4±2.8岁)的数据。与基线相比,CQ/HCQ组在最后一次随访时泪膜破裂时间(<0.0001)和泪液分泌试验I(<0.0001)显著增加,眼表疾病指数(OSDI,<0.0001)和角膜染色(<0.0001)显著降低。在最后一次随访时,CQ/HCQ组的OSDI显著低于对照组(<0.0001)。对照组的角膜染色显著高于CQ/HCQ组(<0.0001)。泪液分泌试验I显示两组之间无显著差异(=0.2)。总之,CQ和HCQ改善了干眼病的症状和体征。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9621/10297605/56595b71d82d/diseases-11-00085-g003a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9621/10297605/2698dec01566/diseases-11-00085-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9621/10297605/fafddcf0ef73/diseases-11-00085-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9621/10297605/56595b71d82d/diseases-11-00085-g003a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9621/10297605/2698dec01566/diseases-11-00085-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9621/10297605/fafddcf0ef73/diseases-11-00085-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9621/10297605/56595b71d82d/diseases-11-00085-g003a.jpg

相似文献

1
Chloroquine and Hydroxychloroquine in the Treatment of Dry Eye Disease.氯喹和羟氯喹治疗干眼症
Diseases. 2023 Jun 12;11(2):85. doi: 10.3390/diseases11020085.
2
Honey-Related Treatment Strategies in Dry Eye Disease.干眼病中与蜂蜜相关的治疗策略
Pharmaceuticals (Basel). 2023 May 18;16(5):762. doi: 10.3390/ph16050762.
3
Placebo administration for dry eye disease: a level I evidence based systematic review and meta-analysis.安慰剂治疗干眼:基于 I 级证据的系统评价和荟萃分析。
Int J Clin Pharm. 2022 Oct;44(5):1087-1101. doi: 10.1007/s11096-022-01439-y. Epub 2022 Aug 8.
4
Systematic review and meta-analysis of efficacy and safety of hydroxychloroquine and chloroquine in the treatment of COVID-19.羟氯喹啉和氯喹啉治疗新冠肺炎疗效与安全性的系统评价和荟萃分析
J Family Med Prim Care. 2021 Jun;10(6):2126-2139. doi: 10.4103/jfmpc.jfmpc_2338_20. Epub 2021 Jul 2.
5
Efficacy of Topical Administration of Corticosteroids for the Management of Dry Eye Disease: Systematic Review and Meta-Analysis.局部应用皮质类固醇治疗干眼疾病的疗效:系统评价与荟萃分析
Life (Basel). 2022 Nov 19;12(11):1932. doi: 10.3390/life12111932.
6
COVID-19 Pandemic - A Narrative Review of the Potential Roles of Chloroquine and Hydroxychloroquine.新型冠状病毒肺炎疫情:氯喹和羟氯喹潜在作用的叙事性综述。
Pain Physician. 2020 Aug;23(4S):S351-S366.
7
Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases.羟氯喹和氯喹在治疗系统性红斑狼疮、类风湿关节炎及相关疾病中的治疗和药理学特性。
Inflammopharmacology. 2015 Oct;23(5):231-69. doi: 10.1007/s10787-015-0239-y. Epub 2015 Aug 6.
8
Acupuncture for the management of dry eye disease.针刺治疗干眼。
Front Med. 2022 Dec;16(6):975-983. doi: 10.1007/s11684-022-0923-4. Epub 2022 Sep 24.
9
Effect of Hydroxychloroquine Treatment on Dry Eyes in Subjects with Primary Sjögren's Syndrome: a Double-Blind Randomized Control Study.羟氯喹治疗对原发性干燥综合征患者干眼的影响:一项双盲随机对照研究。
J Korean Med Sci. 2016 Jul;31(7):1127-35. doi: 10.3346/jkms.2016.31.7.1127. Epub 2016 Apr 20.
10
Chloroquine and Hydroxychloroquine: Efficacy in the Treatment of the COVID-19.氯喹和羟氯喹:对2019冠状病毒病的治疗效果
Pathogens. 2021 Feb 17;10(2):217. doi: 10.3390/pathogens10020217.

引用本文的文献

1
How Advanced are Nanocarriers for Effective Subretinal Injection?用于有效视网膜下注射的纳米载体有多先进?
Int J Nanomedicine. 2024 Sep 10;19:9273-9289. doi: 10.2147/IJN.S479327. eCollection 2024.

本文引用的文献

1
Honey-Related Treatment Strategies in Dry Eye Disease.干眼病中与蜂蜜相关的治疗策略
Pharmaceuticals (Basel). 2023 May 18;16(5):762. doi: 10.3390/ph16050762.
2
Efficacy of Topical Administration of Corticosteroids for the Management of Dry Eye Disease: Systematic Review and Meta-Analysis.局部应用皮质类固醇治疗干眼疾病的疗效:系统评价与荟萃分析
Life (Basel). 2022 Nov 19;12(11):1932. doi: 10.3390/life12111932.
3
Acupuncture for the management of dry eye disease.针刺治疗干眼。
Front Med. 2022 Dec;16(6):975-983. doi: 10.1007/s11684-022-0923-4. Epub 2022 Sep 24.
4
Placebo administration for dry eye disease: a level I evidence based systematic review and meta-analysis.安慰剂治疗干眼:基于 I 级证据的系统评价和荟萃分析。
Int J Clin Pharm. 2022 Oct;44(5):1087-1101. doi: 10.1007/s11096-022-01439-y. Epub 2022 Aug 8.
5
Alternative therapies for dry eye disease.干眼症的替代疗法。
Curr Opin Ophthalmol. 2021 Jul 1;32(4):348-361. doi: 10.1097/ICU.0000000000000768.
6
A Meta-Analysis of the Efficacy of Hyaluronic Acid Eye Drops for the Treatment of Dry Eye Syndrome.透明质酸钠滴眼液治疗干眼症疗效的Meta分析
Int J Environ Res Public Health. 2021 Mar 1;18(5):2383. doi: 10.3390/ijerph18052383.
7
The PRISMA 2020 statement: an updated guideline for reporting systematic reviews.PRISMA 2020 声明:系统评价报告的更新指南。
BMJ. 2021 Mar 29;372:n71. doi: 10.1136/bmj.n71.
8
Safety management in treatment with antimalarials in rheumatology. Interdisciplinary recommendations on the basis of a systematic literature review.抗疟药物治疗中的安全管理。基于系统文献回顾的跨学科建议。
Z Rheumatol. 2021 Feb;80(Suppl 1):1-9. doi: 10.1007/s00393-020-00785-4.
9
Topical Low Dose Preservative-Free Hydrocortisone Reduces Signs and Symptoms in Patients with Chronic Dry Eye: A Randomized Clinical Trial.局部低剂量无防腐剂氢化可的松可减轻慢性干眼患者的体征和症状:一项随机临床试验。
Adv Ther. 2020 Jan;37(1):329-341. doi: 10.1007/s12325-019-01137-8. Epub 2019 Nov 18.
10
Hydroxychloroquine treatment downregulates systemic interferon activation in primary Sjögren's syndrome in the JOQUER randomized trial.羟氯喹治疗下调原发性干燥综合征患者的全身干扰素激活:JOQUER 随机试验。
Rheumatology (Oxford). 2020 Jan 1;59(1):107-111. doi: 10.1093/rheumatology/kez242.